Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT04190758
Enrolling by invitation Observational

GOTHA - The Early Arthritis and Psoriasis Study of Region Västra Götaland, Sweden

NCT04190758 · tracked via the Priya Life Science Sweden tracker
Sponsor
Vastra Gotaland Region
Phase
Observational
Started
2020-01-01
Last updated
2021-10-12

Condition(s) studied

Rheumatoid ArthritisPsoriatic ArthritisArthritisPsoriasisCardiovascular DiseasesObesityLung Diseases

Investigational drug(s) / intervention(s)

Care as usual

Care as usual: No intervention will be given. The study will follow the effects of care as usual.

Study summary

GÖTHA- The early arthritis and psoriasis study of Region Västra Götaland, Sweden - is a longitudinal observational study, which will prospectively and in parallel follow patients with newly diagnosed rheumatoid arthritis (RA, N=1000), psoriatic arthritis (PsA, N=500) and undifferentiated arthritis (N=100), together with patients with psoriasis (N=500). The study will also recruit healthy controls from the general population (N=3000).

The aims of the study are to define predictors for disease course and severity, treatment response, comorbidities, health related quality of life (HRQoL) and health economy.

The study is a collaboration between the department of Rheumatology and the department of Dermatology at Sahlgrenska University Hospital in Gothenburg, and the departments of Rheumatology at the hospitals of Alingsås, Borås, Uddevalla and Skövde, in the west of Sweden.

All patients with newly diagnosed RA, PsA and undifferentiated arthritis at the Rheumatology centers are eligible for inclusion. Patients with psoriasis will be recruited from the Department of dermatology at Sahlgrenska University Hospital.

The patients will be examined at baseline and at one, three, five and ten years. The assessments will include physical examination with evaluation of joints, entheses and skin and validated questionnaires regarding medical history, comorbidities, lifestyle, disease activity, bodily function, socioeconomic factors and HRQoL. Blood samples will be collected. The patients with arthritis will also undergo radiography of the lung, hands and feet, and Cone Beam Computed Tomography (CBCT) of hands and feet.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients with rheumatoid arthritis (RA) meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010 * Patients with psoriatic arthritis (PsA) meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR) PsA * Patients with undifferentiated arthritis defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease * Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks * General population controls, matched for age, sex and residence of living to the included patients. Exclusion Criteria: * Inability to follow study protocol * Swedish language difficulties * Having other concomitant rheumatic diagnose (Sjögrens syndrome is not an exclusion criteria)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinical Rheumatology Research Center (CRRC), Department of Rheumatology, Sahlgrenska University Hospital Gothenburg Sweden

More Vastra Gotaland Region trials in Sweden

Frequency of Hypermobility-Related Problems in Patients With Anorexia Nervosa Enrolling by invitation
Effect of Additional Treatment With NMES After Achilles Tendon Rupture Recruiting
Moving on! A Tailored Treatment in a Primary Care Setting for Individuals With Anxiety Disorders? Recruiting
Optimal Treatment Protocol for Selective Laser Trabeculoplasty - Repeat Trial Enrolling by invitation
Validity and Reliability of Video-Based Functional Physiotherapy Assessment of Subacute Knee Injuries Recruiting

Other trials for the same condition

Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE Recruiting
Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention Active, not recruiting
A Study of AZD0120 in Autoimmune Diseases Recruiting
Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus. Recruiting
Combined High-Intensity Aerobic Training and Resistance Training in Psoriatic Arthritis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04190758 on ClinicalTrials.gov ↗ ← All trials in Sweden